Development of a pH-responsive particulate drug delivery vehicle for localized biologic therapy in inflammatory bowel disease

Yale Journal of Biology and Medicine

Volumn 84, Issue 3, 2011, Pages 285-288

  Capurso, Noah A ^a   Fahmy, Tarek M ^a,b  

^a YALE UNIVERSITY   (United States)

^b Yale University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; DICHLOROMETHANE; EUDRAGIT; GELATIN; INTERLEUKIN 10; RHODAMINE B; METHYLMETHACRYLATE METHACRYLIC ACID COPOLYMER; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; NANOPARTICLE; POLYMETHACRYLIC ACID DERIVATIVE;

ACIDITY; ARTICLE; DRUG DELIVERY SYSTEM; DRUG RELEASE; MICROENCAPSULATION; MICROTECHNOLOGY; PARTICLE SIZE; PH; ENTERITIS; HUMAN; INTESTINE MUCOSA; METABOLISM; METHODOLOGY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SCANNING ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ADMINISTRATION, ORAL; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGEN-ION CONCENTRATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; INTESTINAL MUCOSA; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; POLYMETHACRYLIC ACIDS;

EID: 84856191137     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136:1182-97.
2. Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167-82.
3. Fedorak R, Gangl A, Elson C, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000;119:1473-82.
4. Schreiber S, Fedorak R, Nielsen O, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohns Disease IL-10 Cooperative Study Group. Gastroenterology. 2000;119:1461-72.
5. Lamprecht A, Yamamoto H, Ubrich N, Takeuchi H, Maincent P, Kawashima Y. FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression. Pharm Res. 2005;22:193-9.
6. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther. 2005;315:196-202.
7. Lamprecht A, Schäfer U, Lehr CM. Size-dependent bioadhesion of micro-and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001;18:788-93.
8. Jain R. The manufacturing techniques of various drug loaded biodegradable poly(lactideco-glycolide) (PLGA) devices. Biomaterials. 2000;21:2475-90.
9. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352-5.
10. Bhavsar M, Amiji M. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 2008;15:1200-9.
11. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541-6.